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Abstract: The majority of hypertensive patients need 2 antihypertensive agents to reach goal 
blood pressure. As an estimate, one-third of unselected hypertensive patients may be successfully 
treated with monotherapy, one-third may require 2 and the remaining one-third of patients 
will need 3 antihypertensive agents for effective blood pressure control. However, doctors 
are often hesitant to expand therapy in treated patients whose blood pressure is not lowered to 
goal (therapeutic inertia). Multiple-drug therapy in the majority of hypertensive patients may 
also represent one of several factors responsible for the low rates of adherence with chronic 
antihypertensive treatment. As a consequence, both US and European guidelines recommend 
single pill combinations to lower the number of pills needed in order to increase medication 
adherence and, possibly, reduce therapeutic inertia. For 2 drug combinations, the recently revised 
European (ESC/ESH) guidelines recommend the following options: diuretic plus either calcium 
channel blocker (CCB) or renin–angiotensin system (RAS) blocker (angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker) or CCB plus RAS-blocker. In the absence of 
substantial evidence, neither JNC-7 (from 2003) nor the European guidelines from 2007 give 
any meaningful advice on triple combination treatment. It is therefore of interest that the 2009 
reappraisal of the European guidelines gives preference to the combination of a RAS blocker 
and a CCB plus a diuretic. On the background of the substantial number of patients requiring 
3 drugs for blood pressure control, the recent approval of a single-pill 3-drug combination 
composed in accordance with the above mentioned ESC/ESH recommendations should be 
appreciated.
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Introduction
Hypertension represents a cardiovascular risk factor with a substantial impact on 
morbidity and mortality. In the Global Burdon of Disease study, worldwide mortality in 
the year 2001 was analyzed with respect to underlying risk factors. In that study, between 
7 and 8 million of the approximately 56 million fatalities could be attributed to arterial 
hypertension, supporting the notion that hypertension remains the most aggressive 
risk factor to date.1 The identification of hypertension as an important risk factor has 
been paralleled by continuous efforts to develop more effective and tolerable antihy-
pertensive agents. Thus, over the past 6 decades we have seen an impressive evolution 
of antihypertensive agents (Figure 1). However, in spite of a broad range of available 
antihypertensive drugs, the percentage of hypertensive patients who are treated and 
have a blood pressure in the control range (usually 140/90 mmHg) remains low.2–4 It 
has recently been proposed that the high and even increasing number of patients with 
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uncontrolled blood pressure despite the enormous advances 
in antihypertensive-drug therapy represents a paradox.5 
The term “paradox” refers to something unexpected and 
unexplained and is probably overused in the context of 
medical issues. Thus, the so-called hypertension paradox 
may, at least in part, be explained by epidemiological facts 
(global increase in overweight and obesity) and shortcom-
ings and failures in coping with hypertension by doctors 
and patients.
Doctors may start treatment and nevertheless not 
reach target blood pressure values in their patients due to 
“therapeutic inertia”, defined as a failure to expand therapy 
when treatment goals are unmet. Thus, in a recent Canadian 
study in 7253 treated hypertensive patients, antihypertensive 
therapy was increased in only 13.1% of visits with uncon-
trolled blood pressure.6 Therapeutic inertia may therefore be 
regarded as an additional factor contributing to insufficient 
blood pressure control in hypertensive subjects receiving 
regular care. In that study, predictors of therapeutic inertia 
were treated patients with stage 1 as compared to stage 2 
hypertension and patients on fewer antihypertensive medica-
tions. It may therefore be speculated that the total number of 
medications may be important for the physician’s response to 
a patient not at goal blood pressure with a higher likelihood 
of therapeutic inertia if that number is low.
The most important impediment to reaching goal blood 
pressure in treated hypertensive patients, however, may 
involve patients themselves. Not adhering to a prescribed 
therapy, usually termed non-compliance, remains a great 
challenge to any – especially chronic – drug treatment. In 
this context, it should be recognized that non-adherence with 
drug therapy is of multifactorial origin. Among the many 
reasons and supporting circumstances, the complexity of 
drug therapy itself has been identified as one factor associated 
with non-adherence. This brief review focuses on this issue 
and describes the possible role of so-called fixed-dose 
or single-pill combinations in improving this aspect of 
antihypertensive therapy.
Hypertension – the need  
for combination therapy
Various clinical trials have demonstrated that the majority of 
patients need treatment with multiple antihypertensive agents 
to get to and stay at blood pressure goal. The number of 
antihypertensive agents required for blood pressure control 
averages 2 to 4, with co-morbid conditions such as kidney 
disease or diabetes mellitus imposing even greater drug 
requirement.7,8 For example, in the Hypertension Optimal 
Treatment (HOT) study, an average of 3.3 drugs were 
required in patients aimed at a diastolic blood pressure 
goal of 80 mmHg,8 and in the Anglo-Scandinavian 
Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
(ASCOT-BPLA), most patients (78%) were taking at least 2 
antihypertensive agents by the end of the trial.9 In the Avoiding 
Cardiovascular Events Through Combination Therapy in 
Patients Living with Systolic Hypertension (ACCOMPLISH) 
trial, patients were receiving initial treatment with single-pill 
combinations of 2 antihypertensive agents.10 In this study, 
32.3% of the patients received additional antihypertensive 
agents on top of the highest dose of the dual combination 
after 1 year. This would indicate that about one-third of 
the patients in the ACCOMPLISH trial needed 3 and more 
antihypertensive agents to get and maintain their blood pres-
sure at goal. Acknowledging the wide range of distribution 
for the number of antihypertensive agents used in the dif-
ferent intervention trials, it nevertheless appears reasonable 
to propose a rule of thumb whereby one-third of unselected 
hypertensive patients will have their blood pressure controlled 
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Figure 1 evolution of antihypertensive drugs.
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with a single agent, one-third need 2 drugs and one-third 
will need 3 and more antihypertensive substances. In this 
context, it is of interest to note that hypertension is usually 
defined resistant or refractory to treatment when therapy with 
lifestyle measures and drug therapy of at least three agents 
including a diuretic in adequate doses has failed to lower 
systolic and diastolic blood pressure to goal.2,11,12 According 
to this definition prevalence of resistant hypertension is high: 
for instance in the ALLHAT cohort about 8% of the patients 
were prescribed 4 or more drugs at year 4 (chlorthalidone 
5.5%, amlodipine 8.5% and lisinopril 12.7%).13 The high rate 
of patients receiving 3 drugs in the lisinopril group of the 
ALLHAT trial may be due to the unfavorable add-on proce-
dure for an angiotensin converting enzyme (ACE) inhibitor 
which consisted of atenolol, clonidine or reserpine as step 2 
drugs. However, it may be fair to assume the percentage of 
resistant patient in the range of 5% to 10%.
Two-drug combinations
Significant discrepancies exist on the question of which 
combinations of antihypertensive drugs should be employed. 
While the US-American JNC-7 recommendation from 
2003 asks for a diuretic to be “usually” contained in a 
2-drug combination strategy, the European guideline 
recommends various combinations both with and without a 
diuretic.2,12 More specifically, the recently revised European 
(ESC/ESH) guidelines recommend the following options for 
2-drug combinations: diuretic plus either calcium channel 
blocker (CCB) or renin–angiotensin system (RAS) blocker 
(ACE inhibitor or angiotensin receptor blocker) or CCB 
plus RAS blocker.14 An additional discrepancy between 
US-American and European guidelines concerns the use 
of β-blocker-diuretic combinations which are supported by 
JNC-72 but commented on very critically in the European 
guidelines from 200712 and their reappraisal in 2009.14 It 
appears, however, that much of this discrepancy stems from 
the fact that JNC-7 was published in 2003 when important 
studies influencing the European view such as ASCOT9 and 
ACCOMPLISH10 were not yet published. In the context of 
the current analysis, however, it is important to note that at 
present all recommended 2-drug combinations, according 
to both the US or European guidelines, are available as 
single-drug combinations.
Three-drug combinations
In the absence of large studies investigating triple therapies, 
guidelines were so far unable to make evidence-based 
recommendations. Thus, in JNC-7 it is stated that one should 
“optimize dosages or add additional drugs” in the case of 
uncontrolled hypertension with dual combination therapy.2 
The European guidelines of 2007 make no recommendation 
at all.12 In contrast, the reappraisal of the European guidelines 
from 2009 makes the following statement: “When three 
drugs are required, the most rational combination appears 
to be a blocker of the renin-angiotensin system, a calcium 
antagonist, and a diuretic at effective doses”.14 This recom-
mendation is supported by a recent trial in 2271 hyperten-
sive patients (blood pressure 145/100 mmHg) who were 
randomized to either a triple combination therapy of a RAS 
blocker (valsartan), a CCB (amlodipine) and a diuretic 
(hydrochlorothiazide [HCT]) or to the respective 2-drug 
combinations (RAS blocker + HCT, RAS blocker + CCB, 
CCB + HCT).15 In that short-term study, triple therapy was 
significantly superior to the respective dual therapies in 
reducing mean sitting systolic and diastolic blood pressure 
from baseline to end point. Significantly more patients on 
triple therapy achieved blood pressure control compared 
with each dual therapy.15 It is of interest that this particular 
triple combination has recently been approved as a single-pill 
combination at various doses for antihypertensive treatment 
both in the US and in Europe.
Combination therapy as separate 
pills vs single-pill combinations
Adherence with prescribed medical therapy is generally 
poor.16 Over the past decades, several underlying factors for 
this problem have been identified including forgetfulness 
and conscious decisions by patients.17,18 One among many 
causal factors involved in this context is the complexity of 
therapy, ie, the number of prescribed medications and dosing 
time-points.19,20 As an example, in a retrospective study of 
adherence with antihypertensive and lipid-lowering therapy 
in a US managed care plan, fewer other medications were 
associated with a higher likelihood of adherence (Figure 2).19 
In this context, it is of interest that an increasing number 
of especially elderly patients with multiple morbidities 
do require complex therapies, often resulting in polyphar-
macy.21–23 On the other hand, physicians may be able to 
significantly improve adherence by reducing the pill burden 
of their patients19 which can be achieved by the use of fixed-
dose or single-pill combinations.
Numerous studies have shown that whenever 2 agents are 
needed, eg, for lowering of blood pressure in hypertensive 
patients or for metabolic control in diabetes patients, 
adherence is better when these agents are prescribed as 
single-pill combinations than as separate pills.24–26 As a Vascular Health and Risk Management 2010:6 324
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consequence, many hypertension guidelines therefore 
recommend multiple therapies to be provided as single pill 
combinations.2,12,14
Single-pill combinations have been criticized because of 
lesser flexibility in dosing associated with their use. It should 
be noted, however, that many single-pill combinations 
available offer different doses of, for example, RAS blocker, 
CCB or HCT. Thus, the term single-pill combination may 
indeed be more appropriate than fixed-dose combination. 
On the other hand, for patients with orthostatic problems or 
other co-morbidities such as congestive heart failure, even 
more careful dosing may be appropriate. In such patients, 
single-pill combinations should be used only after therapeutic 
conditions have been stabilized.
In summary, therapeutic inertia on the part of the 
treating physicians and non-adherence on the part of the 
patients are the two main factors responsible for the low 
percentage of treated hypertensive patients who reach 
goal blood pressure. The consequent use of single-pill 
  combinations in accordance with national guidelines will, 
at least in part, improve medication adherence by the 
patients. It seems reasonable, but remains to be shown in 
clinical studies, that the use of fixed-dose combinations will 
also improve therapeutic inertia, since expanding therapy 
up to triple combinations with recommended treatment 
  strategies can be prescribed without increasing the number 
of medications.
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